Inherent change in MammoSite applicator three-dimensional geometry over time by Subhakar Mutyala et al.
BioMed CentralRadiation Oncology
ssOpen AcceResearch
Inherent change in MammoSite applicator three-dimensional 
geometry over time
Subhakar Mutyala*1,2, Walter Choi1,2, Atif J Khan4,5, Ravi Yaparpalvi1,2, 
Alexandra J Stewart3 and Phillip M Devlin4,5
Address: 1Department of Radiation Oncology, Montefiore Medical Center, Bronx NY 10467, USA, 2Department of Radiation Oncology, Albert 
Einstein College of Medicine, Bronx, NY 10461, USA, 3Radiotherapy Department, Royal Marsden Hospital, Sutton, England, UK, 4Department of 
Radiation Oncology, Brigham and Women's Hospital, Boston, MA 02115, USA and 5Department of Radiation Oncology, Dana-Farber Cancer 
Institute, Boston, MA 02115, USA
Email: Subhakar Mutyala* - smutyala@montefiore.org; Walter Choi - wachoi@montefiore.org; Atif J Khan - subrocker@yahoo.com; 
Ravi Yaparpalvi - ryaparpa@montefiore.org; Alexandra J Stewart - astewart@lroc.harvard.edu; Phillip M Devlin - pdevlin@lroc.harvard.edu
* Corresponding author    
Abstract
Accelerated partial breast irradiation is commonly done with the MammoSite applicator, which
requires symmetry to treat the patient. This paper describes three cases that were asymmetric
when initially placed and became symmetric over time, without manipulation.
Background
Accelerated partial breast irradiation (APBI) with the
MammoSite catheter is a new brachytherapy concept in
breast conserving therapy for a subset of patients with
early stage breast cancer [1,2]. The catheter consists of an
inflatable balloon and a central channel for HDR brachy-
therapy. The initial experience [3] describes the ideal tech-
nique for the initial placement of the catheter, either at the
time of lumpectomy or percutaneously under ultrasound
guidance. As the initial Phase I trial describes, in order to
deliver a homogenous dose to the tumor cavity, the bal-
loon on the catheter should be inflated with saline to
achieve a uniform spherical shape. Asymmetry of the
applicator, poor placement, and intrinsic applicator
abnormalities are all grounds for removal of the applica-
tor. In this trial, a number of applicators were removed,
with poor balloon conformance the most common rea-
son for removal. We describe three separate cases where
asymmetric applicators corrected themselves over time




The first patient is a 72 year-old female with an abnormal-
ity noted on a screening mammogram. A stereotactic core
biopsy showed invasive ductal carcinoma. The patient
subsequently had a lumpectomy and axillary node dissec-
tion, with pathology revealing a well-differentiated 9 mm
invasive ductal carcinoma with no lympho-vascular space
invasion. Surgical margins were negative and all lymph
nodes removed on axillary dissection were negative for
tumor. The patient was seen in our department and had a
full history, physical, and pathology review. Based on her
history and pathology, she was deemed a candidate for
APBI with the MammoSite applicator and was placed in
our institutional protocol.
The patient returned for MammoSite placement by ultra-
sound guided percutaneous method approximately 6
weeks after her surgery. The MammoSite was placed suc-
cessfully and inflated with 45 cc of contrast diluted with
sterile water (1:10). Immediate CT scan for planning was
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isotope channel (figure 1). The scan revealed an asymmet-
rical applicator, with the isotope channel off center by 5
mm. The applicator was partially deflated, repositioned
and re-inflated. The applicator was more symmetrical, yet
still not ideal.
The patient returned the following day. Under fluoros-
copy (45 degree tangent with isocenter in center of appli-
cator), it was noted the applicator had changed geometry
from her initial film. The patient underwent a repeat CT
scan using a radio-opaque marker in the isotope channel.
The scan revealed an almost fully symmetrical sphere with
regard to the isotope channel (figure 2). The patient was
re-planned with a fully optimized custom plan, resulting
in an acceptable dose distribution along the parameters of
the protocol. The patient was subsequently treated to 34
Gy in 3.4 Gy BID fractions. The patient underwent a CT
daily, confirming no further change in the applicator over
the course of the treatment.
Case 2
The second patient is a 75 year-old female with a density
seen on a screening mammogram. A 6-month follow-up
mammogram showed an interval increase in size while an
MRI showed an enhancing area in the breast. A core
biopsy was performed, showing poorly differentiated
invasive ductal carcinoma with lobular features, ER+/PR+,
with associated DCIS. The patient had a wire localized
lumpectomy and sentinel node biopsy, with pathology
revealing a 13 mm invasive ductal/lobular carcinoma,
grade III, EIC negative, with no lympho-vascular space
invasion. All surgical margins were negative for tumor and
two sentinel nodes removed were negative for tumor. The
patient requested accelerated partial breast irradiation
with the MammoSite applicator. Based on her pathology
and histology, she was deemed to be a suitable candidate
for APBI.
The patient returned for MammoSite placement by ultra-
sound guided percutaneous method approximately 4
weeks after her surgery. The MammoSite was placed suc-
cessfully and inflated with 40 cc of contrast diluted with
sterile water (1:10). A CT scan for planning was performed
with radio-opaque markers inserted into the isotope
channel (figure 3). The scan revealed an elliptical shaped
applicator due to fibrous scarring.
The patient returned four days later (the following Mon-
day). Under fluoroscopy it appeared the applicator had
changed geometry. The patient was CT scanned again for
re-planning, which revealed a perfectly symmetrical
sphere (figure 4). The patient was re-planned using
PLATO software with a fully optimized custom plan. The
plan was acceptable and the patient was subsequently
treated to 34 Gy in 3.4 Gy BID fractions. Again, the patient
underwent a CT daily, which revealed no further change
in the applicator geometry over the course of the treat-
ment.
CT scan slices from case 2 showing the asymmetry of the center channelFigure 3
CT scan slices from case 2 showing the asymmetry of the 
center channel.
CT scan slices from case 1 showing the asymmetry of the center channelFigure 1
CT scan slices from case 1 showing the asymmetry of the 
center channel.
CT scan slices from case 1 showing the symmetry of the center channelFigure 2
CT scan slices from case 1 showing the symmetry of the 
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The third patient is a 61 year-old female who presented
with a palpable mass in the upper inner quadrant of her
left breast. Mammography revealed a 1 cm distortion of
architecture at the 12 o'clock position of the left breast.
Ultrasound-guided core biopsy revealed moderately dif-
ferentiated infiltrating ductal carcinoma, which was ER/
PR+ and HER-2/neu negative. She underwent breast-con-
serving surgery, with final pathology revealing a 2.5 cm
tumor with negative margins of resection. Three sentinel
lymph nodes were free of metastatic disease. After discus-
sion of her treatment options, the patient elected to
undergo APBI to complete her breast conserving therapy.
Soon after consultation, she underwent percutaneous,
ultrasonographically guided placement of the Mam-
moSite device, which was inflated with 45 cc of 10%
hypaque solution. The planning CT scan was performed
on the same day, and revealed an asymmetric groove
along the ventrolateral portion of the balloon (figure 5).
The catheter was deflated and reinflated, but without
change in the contour of the balloon. The patient's treat-
ment was deferred until reevaluation the following day. At
that time, a CT scan was repeated, revealing that the asym-
metric defect had resolved spontaneously (figure 6). Her
brachytherapy treatment was planned using PLATO soft-
ware with a fully optimized custom plan, delivering 34 Gy
in 10 twice-daily fractions. As per standard procedure, she
underwent daily CT imaging, which confirmed both the
diameter and the symmetry of the balloon.
Discussion
The MammoSite Catheter for APBI has shown to be well
tolerated with acceptable cosmesis for the treatment of
both invasive breast cancers and DCIS [4]. However, even
in experienced hands, the initial MammoSite experience
showed a 10% removal of implant due to asymmetry [3].
All patients described were treated using a single isotope
dwell position. With a single dwell position, asymmetrical
central channels would deliver an inappropriately asym-
metrical dose [5]. Also, with a single dwell position, any
non-spherical balloon placement would deliver an inho-
mogeneous dose. With a newer dose delivery technique,
using dose optimization [6,7] and multiple dwell posi-
tions, some applicators forming "imperfect" spheres can
be correctly treated. However, with only one channel for
isotope delivery, dose optimization cannot correct for
channel asymmetry within the applicator. All optimized
dwell positions still deliver dose around the channel sym-
metrically.
After a patient has a MammoSite applicator placed percu-
taneously, a CT scan for planning is done very shortly
thereafter. The majority of clinics can facilitate placement
of the applicator, a CT scan, and planning within 4–24
hours. In case 1, our patient initially followed the typical
sequence of events. In her situation, the applicator would
have normally been removed, but she wished to wait and
retry applicator manipulation the next day. After only 20
hours, she had intra-balloon geometry change, placing
her isotope channel in the center of the balloon. Our sec-
ond case was placed using the closed technique, with her
initial scan following placement on the same day. Her ini-
tial scan showed an oblong applicator, which would nor-
mally be characterized as an unsuccessful placement. She
was re-scanned after 4 days and without manipulation,
showed a successful placement. The final patient also
underwent percutaneous placement, and her initial CT
was performed approximately 1–2 hours later. Again, the
CT scan slices from case 3 showing balloon symmetryFigure 6
CT scan slices from case 3 showing balloon symmetry.CT scan slices from case 2 showing the symmetry of the center channelFigure 4CT scan slices from case 2 showing the symmetry of the 
center channel.
CT scan slices from case 3 showing the asymmetry of the balloonFigure 5
CT scan slices from case 3 showing the asymmetry of the 
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balloon appeared asymmetric, with marked differences in
the radius of the balloon on cross-sectional imaging,
which would result in inhomogeneous surface doses on a
brachytherapy plan. None of these patients would have
been APBI candidates as per the MammoSite study guide-
lines. With time, however, these patients were converted
to appropriate candidates and were treated successfully.
These three patients show that asymmetry of the Mam-
moSite applicator on an initial planning CT might not be
absolute contraindications for eligibility for MammoSite-
based therapy. Our institutional practice, in line with cur-
rent industry standards, would consider asymmetry of 2-
mm or more to be unacceptable for MammoSite treat-
ment. These cases would have been determined to have
unsuccessful placements, necessitating applicator removal
as defined by the initial study guidelines. However, these
patients' later scans indicated adequate symmetry without
further intervention. Once the MammoSite applicator
became symmetrical and spherical, the patients were
treated without any difficulty. Also the applicator did not
change geometry again, as evidenced by daily CT scans.
Moreover, there have not, to date been instances in which
the MammoSite balloon symmetry did not improve on
repeat imaging. Although our report is admittedly limited
by the small number of cases, it is nonetheless encourag-
ing that in all instances in which balloon asymmetry was
discovered, this finding soon corrected itself and
remained constant thereafter.
In our experience, of approximately 75 MammoSite treat-
ments, these three patients represent the only patients
who would have been deemed poor placement due to
asymmetry only. All three of these patients converted
from inadequate to adequate placement over the course of
1–4 days. No factors seem to indicate this would happen,
since we had all 3 patients (100%) with asymmetrical
applicators convert to symmetrical applicators. Our insti-
tutional policy was to wait as long as a week, before
removing the applicators. This additional week makes the
total time of an indwelling MammoSite catheter to be two
weeks, which is approximately the time the catheter is ind-
welling in the patient if placed at the time of surgery and
found to be tolerable [3].
The MammoSite is still a novel technology for partial
breast irradiation. As the use of MammoSite catheters
increases around the country, the learning curve will con-
tinue to increase. As seen in these cases, in some unsuc-
cessful placements of applicators due to balloon
geometry, the passage of time in days has seemed to cor-
rect the geometry. This suggests that some patients previ-
ously not considered candidates for treatment could still
be treated with APBI using the MammoSite, warranting
further study in a prospective fashion.
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